Alector, Inc.

Alector, Inc. (ALEC) priced its initial public offering on Feb 7, 2019 at $19.00 per share, within its $18.00–$20.00 range, raising $175.8M. At the IPO price its market capitalization was about $1.3B. Morgan Stanley was lead-left underwriter, joined by TD Cowen and Barclays. Wilson Sonsini advised the company and Davis Polk advised the underwriters.

Alector, Inc. is a clinical-stage biopharmaceutical company developing therapies for neurodegeneration under an approach it calls immuno-neurology, which targets immune dysfunction in degenerative brain disorders. Its discovery platform has produced a portfolio of immune system targets and several preclinical programs.

Status

IPO

Ticker

ALEC

Priced

Feb 7, 2019

IPO price

$19.00

Price range

$18.00–$20.00

Raised

$175.8M

Market cap at IPO price

$1.3B

First filed

Jan 7, 2019

Underwriters

Morgan Stanley, TD Cowen and Barclays

Company counsel

Wilson Sonsini

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.